Indy (317) 643-4444 Fishers (317) 567-9100
Tirzepatide Eli Lilly

Mounjaro®

Dual-Action Weight Loss with Blood Sugar Control

Mounjaro® (tirzepatide) is a revolutionary dual-action medication that targets both GIP and GLP-1 receptors for powerful weight loss and blood sugar management.

Regulates appetite
Balances blood sugar
Reduces cravings
Get Started Learn more
20-22% average weight loss
Once Weekly Injection
$275 Per month
Save 75% vs. ~$1100 retail
Basics Benefits How It Works Safety FAQ

What is Mounjaro?

Mounjaro is FDA-approved for type 2 diabetes but widely prescribed off-label for weight loss due to its exceptional efficacy. It works on two key metabolic pathways simultaneously, delivering results that exceed traditional GLP-1 medications.

Clinical Trial Results

In the SURMOUNT-1 trial, patients taking the highest dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks.

FDA Approved For

  • Type 2 Diabetes (primary indication)
  • Weight Loss (off-label, with Zepbound being the approved weight loss version)

Quick Facts

Generic Name
Tirzepatide
Manufacturer
Eli Lilly
Drug Class
Dual GIP/GLP-1 Receptor Agonist
Administration
Subcutaneous injection
Frequency
Once Weekly

Benefits of Mounjaro

1

Industry-leading 20-22% average body weight loss

2

Dual GIP/GLP-1 mechanism for enhanced results

3

Once-weekly self-administered injection

4

Significantly reduces appetite and cravings

5

Excellent blood sugar control for diabetics

6

May improve cardiovascular risk factors

7

Helps preserve lean muscle mass

8

Reduces inflammation markers

How Mounjaro Works

Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism enhances insulin secretion, reduces glucagon, slows gastric emptying, and significantly decreases appetite. The combined effect creates a powerful metabolic shift that helps patients lose substantially more weight than single-receptor medications.

Dual-Action Mechanism

GLP-1 Receptor

Slows gastric emptying, reduces appetite, signals fullness to brain

+

GIP Receptor

Enhances insulin response, improves fat metabolism, amplifies GLP-1 effects

This dual mechanism is why Tirzepatide shows 5-7% greater weight loss than GLP-1-only medications in clinical trials.

Ideal Candidates

  • Adults with BMI ≥30 (obese)
  • Adults with BMI ≥27 with type 2 diabetes or other weight-related conditions
  • Patients who have plateaued on Semaglutide (Ozempic/Wegovy)
  • Those seeking maximum weight loss results
  • Patients who need both weight loss and blood sugar control

Not Recommended For

  • Personal or family history of medullary thyroid carcinoma (MTC)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Currently pregnant or planning pregnancy within 2 months
  • Breastfeeding mothers
  • History of severe pancreatitis
  • Severe gastrointestinal disease
  • Type 1 diabetes

Safety Information

Black Box Warning

Tirzepatide may cause thyroid C-cell tumors in rodents. It is unknown if this occurs in humans. Do not use if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Common Side Effects

Most side effects improve as your body adjusts to the medication.

  • Nausea ~20%
  • Diarrhea ~15%
  • Decreased appetite ~10%
  • Constipation ~8%
  • Injection site reactions ~5%

Serious Side Effects

Rare but important. Contact your provider if you experience any of these.

  • Pancreatitis (rare) - seek immediate medical attention for severe abdominal pain
  • Gallbladder problems - report any upper right abdominal pain
  • Hypoglycemia (when combined with insulin or sulfonylureas)
  • Allergic reactions - stop use if you experience difficulty breathing or severe rash

Frequently Asked Questions

Mounjaro and Zepbound contain the exact same medication (tirzepatide) made by the same company (Eli Lilly). Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is FDA-approved specifically for weight loss. At Premier Weight Loss, we can prescribe either based on your medical history and insurance coverage.

Clinical trials showed patients losing an average of 20-22% of their body weight. For a 250-pound person, that's 50-55 pounds. Individual results vary based on starting weight, adherence, diet, and exercise.

Mounjaro uses newer dual-receptor technology that targets both GIP and GLP-1 pathways. This advanced mechanism delivers superior results but costs more to produce. Our pricing at $275/month (vs. $1,100+ retail) makes it accessible.

Yes! Many patients switch to Mounjaro after plateauing on Ozempic. Our physicians will create a safe transition plan, typically starting you at an appropriate Mounjaro dose based on your current Ozempic regimen.

You inject once weekly into your abdomen, thigh, or upper arm. Rotate injection sites each week. Most patients find it virtually painless. We provide full training at your first visit.

Compare Medications

Tirzepatide

Zepbound®

20-22% $275/mo
Learn more Semaglutide

Wegovy®

15-17% $175/mo
Learn more Semaglutide

Ozempic®

14-15% $175/mo
Learn more
Compare All Medications

Ready to Start Mounjaro?

Take our quick eligibility quiz or schedule a consultation with our medical team.

Check If You Qualify
Indianapolis (317) 643-4444Fishers (317) 567-9100